JP2021509012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021509012A5 JP2021509012A5 JP2020532596A JP2020532596A JP2021509012A5 JP 2021509012 A5 JP2021509012 A5 JP 2021509012A5 JP 2020532596 A JP2020532596 A JP 2020532596A JP 2020532596 A JP2020532596 A JP 2020532596A JP 2021509012 A5 JP2021509012 A5 JP 2021509012A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding fragment
- synuclein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 16
- 102000003802 alpha-Synuclein Human genes 0.000 claims 10
- 108090000185 alpha-Synuclein Proteins 0.000 claims 10
- 208000018737 Parkinson disease Diseases 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 208000009829 Lewy Body Disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000002832 Lewy body dementia Diseases 0.000 claims 3
- 208000032859 Synucleinopathies Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 102000003799 beta-Synuclein Human genes 0.000 claims 1
- 108090000182 beta-Synuclein Proteins 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 102000004963 gamma-Synuclein Human genes 0.000 claims 1
- 108090001121 gamma-Synuclein Proteins 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023092397A JP7627300B2 (ja) | 2017-12-15 | 2023-06-05 | 抗αシヌクレイン抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1720975.0 | 2017-12-15 | ||
| GBGB1720975.0A GB201720975D0 (en) | 2017-12-15 | 2017-12-15 | Anti-alpha synuclein antibodies |
| PCT/EP2018/084697 WO2019115674A1 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023092397A Division JP7627300B2 (ja) | 2017-12-15 | 2023-06-05 | 抗αシヌクレイン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021509012A JP2021509012A (ja) | 2021-03-18 |
| JP2021509012A5 true JP2021509012A5 (enExample) | 2022-01-11 |
| JP7292279B2 JP7292279B2 (ja) | 2023-06-16 |
Family
ID=61009086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532596A Active JP7292279B2 (ja) | 2017-12-15 | 2018-12-13 | 抗αシヌクレイン抗体 |
| JP2023092397A Active JP7627300B2 (ja) | 2017-12-15 | 2023-06-05 | 抗αシヌクレイン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023092397A Active JP7627300B2 (ja) | 2017-12-15 | 2023-06-05 | 抗αシヌクレイン抗体 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11261242B2 (enExample) |
| EP (1) | EP3724224A1 (enExample) |
| JP (2) | JP7292279B2 (enExample) |
| KR (1) | KR102789446B1 (enExample) |
| CN (1) | CN111479826B (enExample) |
| AR (1) | AR115192A1 (enExample) |
| AU (1) | AU2018382530B2 (enExample) |
| BR (1) | BR112020010504A2 (enExample) |
| CA (1) | CA3083199A1 (enExample) |
| CL (1) | CL2020001605A1 (enExample) |
| EA (1) | EA202091478A1 (enExample) |
| EC (1) | ECSP20039623A (enExample) |
| GB (1) | GB201720975D0 (enExample) |
| IL (1) | IL275187B1 (enExample) |
| MA (1) | MA51135A (enExample) |
| MX (2) | MX2020005691A (enExample) |
| MY (1) | MY205948A (enExample) |
| PE (1) | PE20201061A1 (enExample) |
| PH (1) | PH12020551007A1 (enExample) |
| SG (1) | SG11202004502SA (enExample) |
| TN (2) | TN2021000169A1 (enExample) |
| TW (2) | TW202332692A (enExample) |
| UA (1) | UA126295C2 (enExample) |
| UY (1) | UY38010A (enExample) |
| WO (1) | WO2019115674A1 (enExample) |
| ZA (2) | ZA202003542B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| BR112019016374A2 (pt) | 2017-02-17 | 2020-04-07 | Bristol-Myers Squibb Company | anticorpos para alfa-sinucleína e usos dos mesmos |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| CA3111907A1 (en) * | 2018-10-19 | 2020-04-23 | Janssen Vaccines & Prevention B.V. | Anti-synuclein antibodies |
| US20230074436A1 (en) * | 2019-09-20 | 2023-03-09 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| WO2021113464A1 (en) * | 2019-12-04 | 2021-06-10 | Friedman Simon | Protein blocking assembly and methods of making and using |
| KR20240176098A (ko) * | 2023-06-14 | 2024-12-24 | 경상국립대학교산학협력단 | 알파 시누클레인 에피토프를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| AU2002221132A1 (en) | 2000-12-13 | 2002-07-01 | Taisho Pharmaceutical Co. Ltd. | Novel antibody |
| CA2466841A1 (en) | 2001-11-21 | 2003-06-05 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| CA2526900C (en) | 2003-05-19 | 2015-11-24 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in lewy body disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| US20080300204A1 (en) | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
| WO2007021255A1 (en) | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| ES2546863T3 (es) | 2007-02-23 | 2015-09-29 | Prothena Biosciences Limited | Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica |
| JP5558834B2 (ja) | 2007-02-23 | 2014-07-23 | ヤンセン アルツハイマー イミュノセラピー | シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置 |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| JP5747414B2 (ja) | 2008-04-29 | 2015-07-15 | バイオアークティック ニューロサイエンス アーベー | α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン |
| EP3521309A1 (en) | 2008-12-19 | 2019-08-07 | Biogen International Neuroscience GmbH | Human anti-alpha-synuclein antibodies |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| NO2539366T3 (enExample) | 2010-02-26 | 2018-04-07 | ||
| EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| US10989718B2 (en) | 2014-09-11 | 2021-04-27 | Amprion, Inc. | Detection of misfolded alpha synuclein protein |
| US9116157B2 (en) | 2010-11-05 | 2015-08-25 | Brandeis University | Ice-cleaved alpha-synuclein as a biomarker |
| DE102011008153B4 (de) | 2011-01-08 | 2018-08-09 | Aj Roboscreen Gmbh | Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein |
| MX357193B (es) * | 2011-06-23 | 2018-06-29 | Univ Zuerich | Moleculas de union anti-alfa sinucleina. |
| HUE037811T2 (hu) * | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Alfa-szinukleint felismerõ humanizált antitestek |
| CN108517010A (zh) | 2012-01-27 | 2018-09-11 | 普罗典娜生物科学有限公司 | 识别α-突触核蛋白的人源化抗体 |
| WO2013173827A2 (en) | 2012-05-18 | 2013-11-21 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| EP3892638A1 (en) | 2012-05-30 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| EP3071974A2 (en) | 2013-11-19 | 2016-09-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
| WO2015075011A1 (en) | 2013-11-21 | 2015-05-28 | F. Hoffmann-La Roche Ag | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE |
| CA2944402A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| WO2015179867A1 (en) | 2014-05-23 | 2015-11-26 | University Of South Florida | Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinson's disease |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| WO2016040903A1 (en) | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded amyloid beta protein |
| JP6980953B2 (ja) | 2014-09-11 | 2021-12-15 | ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ミスフォールディングタンパク質の検出 |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| DK3341725T3 (da) | 2015-08-25 | 2021-09-06 | Prothena Biosciences Ltd | Fremgangsmåder til detektering af phosphoryleret alpha-synuklein |
| JP6976249B2 (ja) | 2015-11-23 | 2021-12-08 | サンガモ セラピューティクス， インコーポレイテッド | 免疫を工学操作するための方法および組成物 |
| EP3440225A4 (en) | 2016-04-06 | 2020-03-11 | Imago Pharmaceuticals, Inc. | Therapeutic antibodies for treatment of neurodegeneration |
| WO2017207739A1 (en) | 2016-06-02 | 2017-12-07 | Medimmune Limited | Antibodies to alpha-synuclein and uses thereof |
| GB201611840D0 (en) | 2016-07-07 | 2016-08-24 | Univ Court Of The Univ Of Edinburgh The | Alpha-synuclein detection assay |
| US20190194324A1 (en) | 2016-08-23 | 2019-06-27 | The Johns Hopkins University | THERAPEUTIC USES OF LAG3 THE (alpha)-SYNUCLEIN TRANSMISSION RECEPTOR |
| US10889635B2 (en) | 2016-11-15 | 2021-01-12 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| US20180134777A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (11D12) |
| US20180134775A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (7A11) |
| US20180134776A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (4H6) |
| CA3036592A1 (en) | 2016-12-12 | 2018-06-21 | The Michael J. Fox Foundation For Parkinson's Research | Antibodies to human alpha-synuclein |
| BR112018016717A2 (pt) | 2016-12-16 | 2018-12-26 | H Lundbeck As | agentes, usos e métodos |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| EP3567054A4 (en) | 2017-01-06 | 2021-03-10 | ABL Bio Inc. | ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF |
| EP3565636B1 (en) | 2017-01-09 | 2024-01-03 | California Institute of Technology | Use of gut microbiota in the diagnosis of parkinson's disease |
| BR112019016374A2 (pt) | 2017-02-17 | 2020-04-07 | Bristol-Myers Squibb Company | anticorpos para alfa-sinucleína e usos dos mesmos |
| JOP20190227A1 (ar) | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | تركيبات وطرق لعلاج اعتلالات السينوكلين |
| CN110869763B (zh) | 2017-05-16 | 2022-07-29 | 安培里翁公司 | 错误折叠tau蛋白质的检测 |
| WO2018237338A1 (en) | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
-
2017
- 2017-12-15 GB GBGB1720975.0A patent/GB201720975D0/en not_active Ceased
-
2018
- 2018-12-13 PE PE2020000707A patent/PE20201061A1/es unknown
- 2018-12-13 MY MYPI2020002453A patent/MY205948A/en unknown
- 2018-12-13 UA UAA202002941A patent/UA126295C2/uk unknown
- 2018-12-13 US US16/771,993 patent/US11261242B2/en active Active
- 2018-12-13 MX MX2020005691A patent/MX2020005691A/es unknown
- 2018-12-13 EA EA202091478A patent/EA202091478A1/ru unknown
- 2018-12-13 TN TNP/2021/000169A patent/TN2021000169A1/en unknown
- 2018-12-13 CN CN201880080854.1A patent/CN111479826B/zh active Active
- 2018-12-13 WO PCT/EP2018/084697 patent/WO2019115674A1/en not_active Ceased
- 2018-12-13 SG SG11202004502SA patent/SG11202004502SA/en unknown
- 2018-12-13 BR BR112020010504-0A patent/BR112020010504A2/pt unknown
- 2018-12-13 TN TNP/2020/000069A patent/TN2020000069A1/en unknown
- 2018-12-13 AU AU2018382530A patent/AU2018382530B2/en active Active
- 2018-12-13 KR KR1020207019487A patent/KR102789446B1/ko active Active
- 2018-12-13 JP JP2020532596A patent/JP7292279B2/ja active Active
- 2018-12-13 EP EP18829767.5A patent/EP3724224A1/en active Pending
- 2018-12-13 MA MA051135A patent/MA51135A/fr unknown
- 2018-12-13 CA CA3083199A patent/CA3083199A1/en active Pending
- 2018-12-14 TW TW112114559A patent/TW202332692A/zh unknown
- 2018-12-14 AR ARP180103657A patent/AR115192A1/es unknown
- 2018-12-14 TW TW107145283A patent/TWI801469B/zh active
- 2018-12-14 UY UY0001038010A patent/UY38010A/es not_active Application Discontinuation
-
2020
- 2020-06-07 IL IL275187A patent/IL275187B1/en unknown
- 2020-06-12 ZA ZA2020/03542A patent/ZA202003542B/en unknown
- 2020-06-14 PH PH12020551007A patent/PH12020551007A1/en unknown
- 2020-06-15 CL CL2020001605A patent/CL2020001605A1/es unknown
- 2020-07-13 MX MX2024013356A patent/MX2024013356A/es unknown
- 2020-07-14 EC ECSENADI202039623A patent/ECSP20039623A/es unknown
-
2021
- 2021-05-21 ZA ZA2021/03456A patent/ZA202103456B/en unknown
-
2022
- 2022-01-26 US US17/585,174 patent/US12545720B2/en active Active
-
2023
- 2023-06-05 JP JP2023092397A patent/JP7627300B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021509012A5 (enExample) | ||
| HRP20190932T1 (hr) | Molekule protutijela koje se vežu na il-17a i il-17f | |
| JP2016512551A5 (enExample) | ||
| JP2020513791A5 (enExample) | ||
| IL275223B2 (en) | Anti-alpha-synuclein antibodies | |
| JP2018108081A5 (enExample) | ||
| JP2017522892A5 (enExample) | ||
| JP2015504306A5 (enExample) | ||
| JP2020037555A5 (enExample) | ||
| HRP20120759T1 (hr) | Bispecifična veziva specifična između vrsta | |
| JP2014534242A5 (enExample) | ||
| HRP20231134T1 (hr) | Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu | |
| FI3328893T3 (fi) | Mesoteliinia ja cd3:a sitovia bispesifisiä vasta-ainekonstrukteja | |
| JP2019533719A5 (enExample) | ||
| FI2155783T4 (fi) | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| NZ595687A (en) | Anti-tnf-alpha antibodies and their uses | |
| RU2010150348A (ru) | Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применение | |
| JP2010524435A5 (enExample) | ||
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| RU2018146158A (ru) | Антитела | |
| JP2017518040A5 (enExample) | ||
| UA108466C2 (en) | Antibody antagonises c-Met | |
| RU2008140947A (ru) | Антитела к egfl7 и способы их применения | |
| PE20231680A1 (es) | Anticuerpos anti-cd30l y usos de estos | |
| RU2018106456A (ru) | Антитело к epha4 |